Drug Trial Radar · NCT02114229
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
125
Actual
Start
May 14, 2014
Primary completion
Sep 30, 2025
Study completion Sep 2027
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Millennium Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.
- First posted
- Apr 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with recurrent or refractory AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT will receive alisertib as part of age- and risk-adapted chemotherapy. Radiation therapy will be given to children ≥12 months of age. Patients with AT/RT and concurrent extra-CNS MRT are eligible. Alisertib will be administered as a single agent on days 1-7 of each 21-day cycle in all recurrent patients enrolled on Stratum A. For the patients on the newly diagnosed strata (B, C or D), alisertib will be administered in sequence with chemotherapy and radiotherapy. This study has 3 primary strata: (A) children with recurrent/progressive AT/RT or extra-CNS MRT, (B) children \< 36 months-old with newly diagnosed AT/RT, (C) children \> 36 months old with newly diagnosed AT/RT. Children with concurrent MRT will be treated according to age and risk stratification schemes outlined for strata B and C and will have additional treatment for local control. Children with synchronous AT/RT will be treated with age and CNS risk-appropriate therapy, and also receive surgery and/or radiation therapy for local control of the non-CNS tumor. PRIMARY OBJECTIVES * To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive AT/RT (atypical teratoid rhabdoid tumor in the CNS) (Stratum A1) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population. * To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive extra-CNS MRT (malignant rhabdoid tumor outside the CNS) (Stratum A2) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population. * To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis with no metastatic disease (Stratum B1) treated with alisertib in sequence with induction and consolidation chemotherapy and radiation therapy (depending on age) and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. * To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis, with metastatic disease (Stratum B2) treated with alisertib in sequence with induction and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. * To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with no metastatic disease and gross total resection or near total resection (Stratum C1) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. * To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with metastatic or residual disease (Stratum C2) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. * To characterize the pharmacokinetics and pharmacodynamics of alisertib in pediatric patients and to relate drug disposition to toxicity. SECONDARY OBJECTIVES * To estimate the duration of objective response and PFS in patients with recurrent/progressive AT/RT and MRT (Strata A1 and A2). * To estimate PFS and OS distributions in patients with newly diagnosed AT/RT (Strata B1, B2, B3, C1 and C2). * To describe toxicities experienced by patients treated on this trial, specifically any toxicities of alisertib when administered as a single agent or in combination with other therapy over multiple courses and toxicities related to proton or photon radiation therapy. * To describe the patterns of local and distant failure in newly diagnosed patients (Strata B1, B2, B3, C1 and C2). Local control relative to primary-site radiation therapy, with criteria for infield, marginal, or distant failure will also be reported descriptively.
Conditions
- Malignant Rhabdoid Tumor
- Atypical Teratoid Rhabdoid Tumor
Interventions
alisertibDrug
Alisertib will be administered orally at 80 mg/m\^2 per day for enteric coated tablet formulation and 60 mg/m\^2 per day for oral solution formulation.
methotrexateDrug
Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
cisplatinDrug
Cisplatin will be given intravenously (IV): 75 mg/m\^2 IV infusion.
carboplatinDrug
Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
cyclophosphamideDrug
Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
etoposideDrug
Etoposide will be given 100 mg/m\^2 IV infusion. In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day.
topotecanDrug
Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL\*hr.
vincristineDrug
Vincristine will be given 1 mg/m\^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
Surgical resectionProcedure
For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a "second-look" operation is encouraged if and may be performed prior to consolidation therapy.
Radiation therapyRadiation
The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age \> 36 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained response rate of pediatric participants with recurrent or refractory AT/RT treated with alisertib (stratum A1)Time frame: Within 30 weeks after start of alisertib therapy
- Sustained response rate of pediatric participants with recurrent or refractory MRT treated with alisertib (stratum A2)Time frame: Within 30 weeks after start of alisertib therapy
- 3-year progression free survival rate (stratum B1)Time frame: Up to 3 years after the last enrolled patient starts therapy
- 1-year progression free survival rate (stratum B2)Time frame: Up to 1 year after the last enrolled patient starts therapy
- 3-year progression free survival rate (stratum C1)Time frame: Up to 3 years after the last enrolled patient starts therapy
- 1-year progression free survival rate (stratum C2)Time frame: Up to 1-year after the last enrolled patient starts therapy
- Single dose and steady state pharmacokinetics and pharmacodynamics of alisertibTime frame: Treatment Cycle 1 on days 1 and 7
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Lucille Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California
Rady Children's Hospital
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
UF Cancer Center at Orlando Health
Orlando, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota
St. Jude Children's Research Hospital
Memphis, Tennessee
Texas Children's Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.